Zuranolone, a new postpartum depression pill, was found to be safe and effective in a Phase 3 trial. CNN —
The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression – making it the first FDA-approved oral pill in the United States specifically for postpartum depression, a serious mental illness that can develop in about 1 in 7 new mothers after childbirth.
On Friday, the FDA announced that the treatment, to be sold under the brand named Zurzuvae, has been approved as a once-daily pill taken over the course of 14 days.“Postpartum depression is […]
See also Remittances to Mexico hit record, but strong peso softens impact
Powered by Inline Related Posts